Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744711 | 0.81 | TSHR (0.46) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL13638820 | 0.81 | TSHR (0.46) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL23480156 | 0.81 | MMP1 (0.50) | TSHRACACBHPGDSMN1; SMN2THRB | |
| SCHEMBL67778 | 0.79 | TSHR (0.44) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL1036877 | 0.78 | — | — | |
| SCHEMBL68679 | 0.76 | — | — | |
| SCHEMBL14948951 | 0.75 | TSHR (0.41) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL24242137 | 0.74 | SMN1; SMN2 (0.49) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL24327805 | 0.73 | ACACB (0.39) | TSHRACACBHPGDSMN1; SMN2LMNA | |
| SCHEMBL24313555 | 0.73 | KMT2A (0.42) | TSHRACACBHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010100127-A1 | DISUBSTITUTED IMIDAZOLE DERIVATIVES AS MODULATORS OF RAF KINASE | NOVARTIS AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | TSHR 3286/4885ACACB 1921/4885HPGD 2043/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | TSHR 3980/4885ACACB 1032/4885HPGD 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.